Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Allylestrenol

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    European Commission (EC) Approves Henlius And Organon's Poherdy
    European Commission (EC) Approves Henlius And Organon's Poherdy

    29 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/european-commission-ec-approves-henlius-and-organons-poherdy-pertuzumab-the-first-approved-biosimilar-to-perjeta-pertuzumab-in-europe-302757076.html

    PR NEWSWIRE
    29 Apr 2026
    Share Share
    Organon to Report Q1 2026 Results and Host Call on May 7
    Organon to Report Q1 2026 Results and Host Call on May 7

    16 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260416918808/en/Organon-To-Report-First-Quarter-2026-Results-and-Host-Conference-Call-on-May-7-2026

    BUSINESSWIRE
    16 Apr 2026
    Share Share
    Organon's VTAMA Wins Strong AAD Guideline Nod for Kids' AD
    Organon's VTAMA Wins Strong AAD Guideline Nod for Kids' AD

    15 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260415800059/en/Organons-VTAMA-tapinarof-cream-1-Granted-Strong-Recommendation-in-the-2026-American-Academy-of-Dermatology-Guidelines-for-Pediatric-Atopic-Dermatitis

    BUSINESSWIRE
    15 Apr 2026
    Share Share
    Sun Pharma Granted Relief As Ahd Co Restricted From 'Esiraft' Use
    Sun Pharma Granted Relief As Ahd Co Restricted From 'Esiraft' Use

    13 Apr 2026

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bombay-high-court-rules-against-meghmani-lifesciences-in-trademark-dispute-with-sun-pharma/articleshow/130219988.cms

    ECONOMICTIMES
    13 Apr 2026
    Share Share
    Organon VTAMA Shows Ph3 Skin Clearance In AD Patients
    Organon VTAMA Shows Ph3 Skin Clearance In AD Patients

    27 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260327556082/en/Organon-Debuts-New-Analysis-of-VTAMA-tapinarof-cream-1-Phase-3-Pooled-Data-Demonstrating-Early-and-Consistent-Skin-Clearance-and-Itch-Improvement-in-Atopic-Dermatitis-Patients-Down-to-2-Years-of-Age

    BUSINESSWIRE
    27 Mar 2026
    Share Share
    Organon VTAMA Ph 3 Data Show Early Sleep Gains in Pediatric AD
    Organon VTAMA Ph 3 Data Show Early Sleep Gains in Pediatric AD

    27 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260227912195/en/New-Analysis-of-Organons-VTAMA-tapinarof-cream-1-Phase-3-Data-Showed-Early-and-Consistent-Improvement-in-Patient-Reported-Sleep-Subdomains-in-Pediatric-Patients-Down-to-2-Years-of-Age-with-Atopic-Dermatitis

    BUSINESSWIRE
    27 Feb 2026
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.